A perpetual loser at the high stakes game of Alzheimer's research, Roche concedes another amyloid flop
The amyloid beta theory that has driven billions of dollars in failed Alzheimer’s research has taken yet another body blow.
Roche — and specifically its big …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
